Topical Sirolimus for the Treatment of Pachyonychia Congenita (PC)

Phase 1b Clinical Trial Using Topical Sirolimus for the Treatment of Pachyonychia Congenita

Sponsors

Lead Sponsor: TransDerm, Inc.

Collaborator: Pachyonychia Congenita Project

Source TransDerm, Inc.
Brief Summary

A study to evaluate safety and efficacy of topical sirolimus to treat plantar keratoderma in adults with PC. Subjects may receive either placebo or treatment with at least 1 foot receiving topical sirolimus at some time. For certain phases of the study treatment assignment to the right and left foot will be randomized in a double blind fashion. Blood levels will test systemic absorption of sirolimus. Other safety and efficacy measures will be taken through the 39-week study duration. Funding Source - FDA OOPD

Overall Status Completed
Start Date 2014-01-01
Completion Date 2015-11-01
Primary Completion Date 2015-07-01
Phase Phase 1
Study Type Interventional
Primary Outcome
Measure Time Frame
Evaluation of Systemic Absorption Through Measurement of Serum Sirolimus Trough Levels Two weeks and every 1-2 months for 24 weeks or within 2 weeks after the last dose of study drug
Secondary Outcome
Measure Time Frame
Weekly Assessments Recorded in the PC Quality of Life Index Weekly for 39 weeks
Daily Assessments Recording in the PC Measurement Diary Weekly for 39 weeks
Enrollment 15
Condition
Intervention

Intervention Type: Drug

Intervention Name: 1% sirolimus cream (TD201 1%)

Description: 1% sirolimus cream (TD201 1%)

Arm Group Label: Split-body 1% sirolimus cream (TD201 1%)

Eligibility

Criteria:

Inclusion Criteria: Subjects must: - Be capable of understanding the purpose and risks of the study and sign a written Informed Consent Form (ICF) - Be male or female ≥ 16 years of age at the time of the screening visit - Have a confirmed diagnosis of PC by genotyping (e.g., familial) and clinically correlated painful keratoderma. - Have roughly symmetrical calluses of similar severity on the plantar surface of both feet - Women of childbearing potential must have a negative serum pregnancy test - Subjects, whether male or female, with reproductive potential and who are sexually active must agree to use double-barrier contraception methods Exclusion Criteria: A Subject with any of the following criteria is not eligible for inclusion in this study: - Use of other investigational drugs within 30 days of the screening visit and/or has not recovered from any side effects of prior investigational drugs or procedure in the affected area (e.g., a biopsy) - Significant condition in the dermatologic treatment area such as trauma, or nonhealing chronic wound - Pregnant or nursing (lactating) female, or a positive serum pregnancy test - Active infection either systemic or local near the site of treatment requiring chronic or prolonged use of antimicrobial agents - Known immunodeficiency including: Hepatitis A; Hepatitis B; Hepatitis C; Human Immunodeficiency Virus (HIV) Prior and Current Treatment - Unable to be discontinued from drugs known to either be inducers or inhibitors of CYP3A4/5 enzymes - Unable to be discontinued from drugs known to be P-glycoprotein inhibitors

Gender:

All

Minimum Age:

16 Years

Maximum Age:

N/A

Healthy Volunteers:

No

Overall Official
Last Name Role Affiliation
Roger L Kaspar, PhD Study Chair TransDerm, Inc.
Location
Facility: Stanford University
Location Countries

United States

Verification Date

2016-10-01

Responsible Party

Type: Sponsor

Keywords
Has Expanded Access No
Condition Browse
Number Of Arms 1
Arm Group

Label: Split-body 1% sirolimus cream (TD201 1%)

Type: Experimental

Description: This is a split-body design. Subjects will self-administer 1% topical sirolimus cream or placebo cream (no drug, vehicle control) on the plantar surface of each foot. At least one foot will be treated with topical sirolimus at some time during the study. Application will be one time daily for a total of 26 weeks. There will be an additional follow-up visit 3 months after the last application of study drug. The total duration of the study is 39 weeks.

Patient Data Undecided
Study Design Info

Allocation: Randomized

Intervention Model: Single Group Assignment

Primary Purpose: Treatment

Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact [email protected]. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Research News